|Bid||8,779.00 x 0|
|Ask||8,780.00 x 0|
|Day's range||8,750.00 - 8,848.00|
|52-week range||6,499.80 - 9,081.00|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||41.86|
|Earnings date||12 Nov 2021|
|Forward dividend & yield||2.02 (2.30%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||95.81|
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.
Brokerages' race to the bottom in trading fees has been a breakthrough in helping to make investing less cumbersome to newcomers. While high commissions used to be a costly obstacle for new investors and discouraged some from investing altogether, that's now less of an issue. In fact, a recent study by discount broker Charles Schwab found that 15% of current U.S. investors bought their first shares just last year.
WILMINGTON, Del., October 15, 2021--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. This novel dose and schedule